ITI is a program of The Task Force for Global Health.
Zambia began full SAFE implementation for trachoma elimination in 2010 and Zithromax® was approved for trachoma MDAs in four districts. A Trachoma Action Plan (TAP) workshop was conducted in July 2011 and the National Trachoma Task Force established in 2012. The first major MDA for trachoma elimination also took place in 2012.
The national program convened a stakeholder meeting with implementing partners in February 2016 to finalize survey methodology for mapping districts previously surveyed using non-standard methodology. Prevalence mapping using the Tropical Data platform began in May 2016 in 42 districts and the results indicate that the trachoma burden in Zambia is far less severe than once expected.
MDAs and other aspects of the SAFE strategy have been supported by Sightsavers, Geneva Global, Orbis, Lions Aid Norway and Operation Eyesight Universal with funding from the Department for International Development, UK (DFID) and the Queen Elizabeth Diamond Jubilee Trust.
CURRENT IMPLEMENTATION STATUS
A TAP workshop was organized in February 2017 to prepare a budget and plan for SAFE implementation over the next three years based on new prevalence data.
The national program requested Zithromax® allocations for MDAs in 12 additional districts in 2017 (in addition to the 14 districts that were requested at TEC 14) which were found to have TF over 5% in the 2016 mapping exercise. Three of the 12 districts will require three rounds of MDAs.
All 2017 and 2018 MDAs will be supported by Sightsavers and implemented by the national program with support from Lions Aid Norway, Operation Eyesight Universal, and Orbis.
Zithromax® Shipments by Year